Healthcare, Pharma & Life Sciences

NetDragon Funds HKUST Medical Technology Professorship

Image
NetDragon Funds HKUST Medical Technology Professorship

Hong Kong – September 16, 2026 -- NetDragon Websoft Holdings Limited (Hong Kong Stock Code: 777) has agreed to fund a new "NetDragon Professorship in Medical Technology" at The Hong Kong University of Science and Technology (HKUST), targeting research at the intersection of engineering and medicine.

NetDragon commits funding to back a distinguished HKUST engineering scholar

The professorship will be conferred on a scholar from HKUST's School of Engineering in recognition of research contributions, with the goal of accelerating breakthroughs in precision medicine and digital health. The signing ceremony took place on the HKUST campus, witnessed by HKUST President Prof. Nancy Ip and NetDragon Chairman and Executive Director Dr. Liu Dejian. The agreement was formally signed by Prof. Charles Ng, HKUST's Vice-President for Institutional Advancement, and Dr. Simon Leung, NetDragon's Vice Chairman and Executive Director.

BPI Convenes Pharmacy, Insurer, Politics Panel on Prevention at Expopharm

Image
BPI Convenes Pharmacy, Insurer, Politics Panel on Prevention at Expopharm

Berlin – – September 16, 2026 -- The Bundesverband der Pharmazeutischen Industrie (BPI) will bring together four senior stakeholders from pharmacy, politics, health insurance and the pharmaceutical industry on September 16, 2026, to debate how prevention can be scaled across Germany's healthcare system.

BPI schedules prevention panel for expopharm networking breakfast

The discussion, titled "Prävention als Chance für unser Gesundheitssystem," takes place at 9:00 a.m. (doors open 8:30 a.m.) in Hall A3 of the pharmaworld area at expopharm, as part of the BPI's networking breakfast.

Pharmacist chamber pushes for pharmacies as broader health navigators

Franziska Scharpf, Vice President of the Bundesapothekerkammer, argues that pharmacies should expand their role as health navigators through screenings, pharmaceutical counseling, vaccination services and guided self-medication.

Sectra Extends Enterprise Imaging Deal to All of Region Østdanmark

Linköping – September 16, 2026 -- Sectra has signed a contract extension to expand its Sectra One enterprise imaging solution from the Capital Region in Denmark to cover the whole of the newly formed Region Østdanmark, created by the merger of the Capital Region and Region Zealand.

Merged Danish region unifies imaging systems across eastern Denmark

Hospitals joining from Region Zealand will move onto the same cloud-delivered platform already running in the Capital Region, giving clinicians access to a patient's prior images regardless of which hospital performed the exam. The system will be used across all of the region's hospitals for reviewing and storing images in radiology, breast imaging, nuclear medicine and clinical physiology.

AdJane Details Plan to Add Mucosal Booster to mRNA Vaccine Regimens

Image
AdJane Details Plan to Add Mucosal Booster to mRNA Vaccine Regimens

Delft – September 16, 2026 -- AdJane Biosciences has published a White Paper outlining a strategy to add a proprietary intranasal booster to existing intramuscular respiratory vaccines, targeting the mucosal immunity gap left by current mRNA shots.

Phase I data show intranasal booster induced significant nasal IgA responses in mRNA-primed subjects

In a post-hoc subset of participants from AdJane's completed Phase I study who had previously received Pfizer and/or Moderna COVID-19 mRNA vaccines, a subsequent intranasal dose of an Nm-nOMV vaccine displaying SARS-CoV-2 Spike was well tolerated and generated significant nasal IgA responses. AdJane says this provides initial human evidence for a heterologous prime-boost approach: systemic priming via existing intramuscular vaccines followed by a mucosal Nm-nOMV booster delivered intranasally.

AdJane Unveils Mucosal Booster Strategy for Respiratory Vaccines

Image
AdJane Unveils Mucosal Booster Strategy for Respiratory Vaccines

Delft – September 16, 2026 -- AdJane Biosciences has published a white paper outlining a strategy to add mucosal immune stimulation to existing intramuscular respiratory vaccine regimens, using its clinically validated Nm-nOMV platform derived from Neisseria meningitidis outer membrane vesicles.

AdJane targets the mucosal gap left by intramuscular respiratory vaccines

Current intramuscular respiratory vaccines induce strong systemic immunity and protect against severe disease, but generate limited protection at the respiratory mucosa, the point where pathogens first enter the body. The company's white paper, titled 'Boosting mRNA: Mucosal Immunity and a Platform Beyond It,' argues that mucosal IgA responses can reduce transmission at the point of entry, a target public health bodies are pursuing alongside severe-disease prevention.

CordenPharma Invests €80M to Hit 500M Sterile Injectable Units Yearly

Image
CordenPharma Invests €80M to Hit 500M Sterile Injectable Units Yearly

Basel, Switzerland – September 16, 2026 -- CordenPharma has committed a multi-year €80 million investment to expand sterile injectable manufacturing at its FDA & EMA-approved Caponago site near Milan, Italy, targeting a total production capacity of 500 million units per year.

CordenPharma finalizes €13 million land and building acquisition to expand Caponago footprint by over 50%

The company completed the purchase of an 11,000 m2 commercial building and 26,000 m2 of adjacent land on 28 July 2026, adjacent to its existing late-stage aseptic fill & finish area. The new space can accommodate at least four aseptic fill & finish lines, four visual inspection lines and four packaging lines, with room for customer-owned lines, large-scale lyophilization and auto-injector assembly.

Insilico Doses First Patient in Phase III Trial of AI-Discovered IPF Drug

Image
Insilico Doses First Patient in Phase III Trial of AI-Discovered IPF Drug

Cambridge – – September 16, 2026 -- Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, a Phase III trial of Rentosertib, marking what the company calls the world's first late-stage clinical study of a drug candidate discovered and developed using generative AI.

Peking and Shanghai hospitals simultaneously enroll first patients

The dosing occurred at Peking Union Medical College Hospital, with Shanghai Pulmonary Hospital enrolling its own first patient on the same day. Professor Zuojun Xu of Peking Union Medical College Hospital serves as Leading Principal Investigator, with Academician Nanshan Zhong and President Chang Chen of Shanghai Pulmonary Hospital as Co-Leading PIs.

BioEdge Expands Batch-Level COA Access for Research Peptides

Miami – September 16, 2026 -- BioEdge Research Labs has begun publishing batch-specific Certificates of Analysis (COAs) directly on its product pages, allowing laboratory customers to verify identity and purity data for the exact lot they receive rather than relying on aggregated supplier summaries.

Each lot now carries its own matched documentation

Instead of a single certificate applied across multiple production runs, every vial supplied by the Miami-based company is assigned a lot number tied to a corresponding COA, letting researchers cross-check the physical material against its specific record.

Independent labs handle identity and purity testing

The underlying analysis is conducted by a third-party laboratory rather than BioEdge itself, covering identity verification via mass spectrometry, purity assessment via high-performance liquid chromatography, and contaminant screening.

iFlex Stretch Studios Adds AI-Powered Kinotek 3D Movement Tech

Image
iFlex Stretch Studios Adds AI-Powered Kinotek 3D Movement Tech

Newport Beach, Calif. – September 16, 2026 -- iFlex Stretch Studios, the assisted stretching franchise under Sequel Brands, has integrated Kinotek's markerless 3D movement assessment technology across its studio network, giving certified stretch therapists AI-driven data to personalize client sessions.

Kinotek's markerless system scans clients in seconds without sensors or wearables

The technology captures a client's body in motion before a session begins, analyzing range of motion, symmetry, and movement quality without requiring markers or sensors. Therapists use the resulting data to build personalized stretching plans, recommend at-home mobility work, and suggest recovery products tailored to individual goals.